Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price after the company reported lower-than-expected Q2 2026 revenue and substantially cut its full-year guidance. The firm is encouraging shareholders who purchased Myriad securities to join the investigation, citing potential claims related to the company's prior reiteration of higher revenue guidance just months before the revision.
MYGN Maintained by Stephens & Co. -- Price Target Lowered to $3.
Stephens & Co. analyst Mason Carrico has maintained an "Equal-Weight" rating for Myriad Genetics (MYGN) but lowered its price target from $5.00 to $3.00, a 40% reduction. This reflects growing concerns about the company's financial performance, despite GuruFocus indicating the stock is 73.9% undervalued with a GF Value of $11.46 against its current price of $2.99. However, MYGN shows moderate overall performance with a GF Score of 55/100, hampered by unprofitability and a high forward P/E, suggesting caution for investors.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported Q2 2026 revenues that were below Wall Street consensus and subsequently cut its full-year 2026 revenue guidance, citing reimbursement pressures and other issues. The firm encourages investors who purchased Myriad securities to come forward and assist in the investigation.
Marquis Who's Who Honors Ben Wheeler for Expertise in Finance and Healthcare
Ben Wheeler has been recognized by Marquis Who's Who for his significant achievements and leadership in both the finance and healthcare sectors. As the Chief Financial Officer at Myriad Genetics, Inc., he oversees crucial financial functions, investor relations, and strategic initiatives, playing a key role in the company's growth and stability. His career also highlights his expertise in acquisitions, capital markets, and people development, reinforced by his strong academic background and professional certifications.
Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake
Glenview Capital Management and Larry Robbins have reported that they no longer hold a significant ownership stake in Myriad Genetics (MYGN). An SEC filing (SCHEDULE 13G/A) indicates that as of June 30, 2026, they beneficially own 0 shares, representing 0% of the outstanding common stock. This filing confirms their exit from a previously reported ownership position in the company.
Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing
Vestal Point Capital, LP and its Chief Investment Officer Ryan Wilder have disclosed a 6.1% stake in Myriad Genetics, Inc. (MYGN) through a Schedule 13G filing. The reporting group beneficially owns 5,735,000 shares of common stock, representing 6.1% of the 94,448,210 outstanding shares as of May 1, 2026. This passive investment grants them shared voting and dispositive power over these shares, held via a Vestal Point fund and a managed account.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported lower-than-expected Q2 2026 revenues, cut its full-year 2026 revenue guidance, and suspended its adjusted EBITDA guidance, citing reimbursement pressure and collections issues. The firm is encouraging investors who purchased Myriad securities to learn more and potentially assist in a class action.
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP is investigating Myriad Genetics, Inc. (NASDAQ: MYGN) following a significant stock price decline after the company reported an 11% year-over-year revenue decrease in Q2 2026 and reduced its full-year guidance. The decline was attributed to issues with payer reimbursement and revenue-cycle friction, leading to a 47% drop in Myriad's stock price. The law firm is encouraging investors who purchased Myriad Genetics securities to contact them regarding potential securities laws violations.
Myriad Genetics Faces Multiple Investor Investigations
Myriad Genetics (NASDAQ: MYGN) is facing multiple investor investigations from several law firms after reporting weaker-than-expected second-quarter results and sharply reducing its 2026 revenue outlook. The company's stock lost nearly half its value following the announcement, prompting inquiries into whether Myriad Genetics or its management made false or misleading statements to investors. The investigations are focused on the significant revenue decline, reduced guidance, and issues related to reimbursement and collection.
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN
Dimensional Fund Advisors LP significantly reduced its stake in Myriad Genetics, Inc. by 42.6% in the first quarter, selling over half a million shares. This move comes as institutional investors hold a substantial portion of the company, and analysts have become more bearish, issuing "Reduce" ratings and lowering price targets. Myriad Genetics also reported weaker-than-expected quarterly financial results, missing revenue and earnings estimates.
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN
Assenagon Asset Management S.A. significantly reduced its stake in Myriad Genetics, Inc. by 28.7% in the second quarter, selling over 415,000 shares. This divestment follows Myriad Genetics reporting disappointing quarterly results, missing analyst expectations for both earnings and revenue, and experiencing a year-over-year revenue decline. Consequently, analyst sentiment has soured, leading to several price target cuts and a consensus "Reduce" rating for the stock.
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (NASDAQ: MYGN) securities. This investigation follows Myriad's Q2 2026 revenue report, which showed an 11% year-over-year decrease and fell short of Wall Street estimates, leading the company to cut its full-year revenue guidance and suspend adjusted EBITDA guidance. Investors are encouraged to contact the firm if they have information or purchased Myriad securities.
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky is investigating Myriad Genetics (MYGN) for potential securities law violations after the company reported lower-than-expected Q2 2026 revenue, cut its full-year revenue guidance, and suspended adjusted EBITDA guidance. The investigation focuses on whether Myriad Genetics made materially false or misleading statements regarding its financial outlook, especially since revenue guidance was reiterated just three months prior to the reduction. Investors who suffered losses on their MYGN investment are encouraged to contact Levi & Korsinsky for a free evaluation.
Myriad Genetics And 2 Other Promising Penny Stocks For Your Watchlist
This article identifies three promising "penny stocks" for investors to consider: Myriad Genetics (MYGN), Claros Mortgage Trust (CMTG), and Nextdoor Holdings (NXDR). It highlights their financial health, operational details, market capitalization, and recent performance, noting both challenges and potential for growth in a thriving market. The analysis aims to provide long-term focused insights based on fundamental data, while cautioning that it is not financial advice.
Myriad Genetics And 2 Other Promising Penny Stocks For Your Watchlist
This article identifies three promising penny stocks—Myriad Genetics (MYGN), Claros Mortgage Trust (CMTG), and Nextdoor Holdings (NXDR)—that exhibit strong financial health despite current challenges. Myriad Genetics is expanding its market reach through strategic partnerships, Claros Mortgage Trust has a solid cash runway despite unprofitability, and Nextdoor Holdings is reducing losses with robust cash flow and no debt. The article suggests these companies could offer unique opportunities for investors seeking value and growth in a thriving market.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation was triggered by Myriad's Q2 2026 revenue shortfall and a substantial cut in its full-year 2026 revenue guidance, which management attributed to reimbursement pressure, collections issues, and weaker prenatal performance. The firm is encouraging stockholders to connect and assist with the investigation, emphasizing that there is no cost to investors for their representation.
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities law violations. This investigation follows Myriad's Q2 2026 financial results, which showed an 11% year-over-year revenue drop, reduced full-year guidance, and suspended EBITDA guidance, causing a sharp decline in share price. SBS is encouraging affected shareholders to join the fraud investigation to discuss their rights.
Myriad Genetics (NASDAQ:MYGN) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen has downgraded Myriad Genetics (NASDAQ:MYGN) to a "Sell" rating from "Hold," citing the company's recent earnings miss and declining revenue. The stock opened significantly below its moving averages, and the analyst consensus for Myriad Genetics is now "Reduce" with an average price target of $5.38. Other analysts have also issued "Sell" or "Strong Sell" ratings, and the company has seen some insider selling recently, although there was also an insider purchase.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported Q2 2026 revenues that were 11% lower year-over-year and below Wall Street expectations, leading the company to cut its full-year revenue guidance and suspend adjusted EBITDA guidance. The firm is encouraging investors who purchased Myriad securities to join the investigation.
State Street Corporation (NYSE: STT) discloses 5.3% holding in Myriad Genetics
State Street Corporation has disclosed a 5.3% beneficial ownership in Myriad Genetics, Inc. (MYGN), amounting to 4,985,060 shares. This ownership is managed through various asset management subsidiaries, with shared voting and dispositive power over the shares. The filing, a SCHEDULE 13G, indicates a passive investment, confirming no sole voting or dispositive power by State Street itself.
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating Myriad Genetics, Inc. (MYGN) after the company reported Q2 2026 revenues below Wall Street expectations and significantly cut its full-year 2026 revenue guidance. The firm encourages stockholders to contact them to learn more about the investigation into potential claims on behalf of purchasers of Myriad securities. Myriad attributed the financial shortfall to reimbursement pressures, collections issues, and lower revenue per test.
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Myriad Genetics, Inc. (MYGN) after the company reported significantly lower-than-expected Q2 2026 revenue and drastically cut its full-year 2026 guidance. This announcement followed Myriad Genetics reiterating stronger guidance just three months prior, leading to a stock price drop. The firm encourages affected investors to contact them to assist with the investigation.
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP
Kirby McInerney LLP is investigating Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities fraud following a significant 47% stock price decline on July 31, 2026. This drop occurred after Myriad reported an 11% year-over-year revenue decrease in Q2 2026, reduced its full-year revenue guidance, and attributed the issues to lower reimbursement and "payer-generated revenue-cycle friction." The law firm is seeking investors who purchased Myriad securities to discuss their rights.
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP
Kirby McInerney LLP has announced an investigation into Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities fraud. This follows Myriad Genetics' report of an 11% year-over-year revenue decline in Q2 2026, reduced full-year guidance, and a significant stock price drop after the announcement. The investigation will examine whether the company violated federal securities laws.
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP
Kirby McInerney LLP is investigating Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities fraud following a significant decline in revenue and stock price. The company reported an 11% year-over-year revenue decrease in Q2 2026, reduced its full-year guidance, and saw its stock drop 47% after acknowledging issues with payer-generated revenue-cycle friction. Investors who purchased Myriad securities are encouraged to contact the firm regarding their rights.
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is investigating Myriad Genetics, Inc. (MYGN) for potential federal securities law violations after the company reported an 11% year-over-year revenue decline and reduced its annual guidance. This decline was attributed to issues like lower reimbursement and unfavorable estimate changes, leading to a 47% drop in Myriad Genetics' shares on July 31, 2026. Investors who suffered losses are urged to contact Johnson Fistel for potential recovery options.
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.34, Implies 87% Upside
Myriad Genetics, Inc.'s average 12-month price target has been lowered by analysts from $5.44 to $5.34, with forecasts ranging from $3 to $10. This updated target suggests an approximate 87% potential upside based on the July 31 closing price. Despite the target cut, the consensus rating for MYGN stock remains "Hold" among 9 analysts, including 2 Buys, 5 Holds, and 2 Sells.
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)
Levi & Korsinsky, LLP has announced an investigation into Myriad Genetics (NASDAQ: MYGN) after the company significantly cut its full-year 2026 revenue guidance and suspended adjusted EBITDA guidance. This comes just three months after reaffirming higher revenue projections, leading to investor losses. The firm is encouraging affected shareholders to submit their loss information for a potential securities fraud claim.
Why Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook On Prenatal Weakness
Myriad Genetics (MYGN) shares dropped 49% after the company cut its 2026 revenue outlook to US$770-790 million, down from US$190.7 million, primarily due to weaker Prenatal Health test volumes. Despite a narrowed net loss, the reduced forecast highlights ongoing pressure on test volumes and pricing, making the stabilization of Prenatal Health a key focus for investors. The company is attempting to diversify through oncology partnerships, but immediate concerns remain about prenatal test demand and reimbursement.
Why Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook On Prenatal Weakness
Myriad Genetics (MYGN) shares fell 49.0% after the company cut its full-year 2026 revenue outlook due to weaker Prenatal Health test volumes and more cautious assumptions for revenue per test. While the company's net loss narrowed, the immediate pressure on its Prenatal Health segment raises concerns for investors. The article highlights Myriad's strategy to diversify into oncology to offset these pressures and mentions that analysts were already cautious about the company's growth prospects.
MYGN Slides As Myriad Genetics Slashes 2026 Revenue Outlook
Myriad Genetics Inc. (MYGN) stock slid by 45.72% after the company slashed its 2026 revenue outlook to $770M-$790M from a prior $860M-$880M, falling short of Street expectations. This reduction was attributed to competitive genetic testing advancements, weaker Q2 performance, and increased payer friction, leading TD Cowen to lower its price target to $4. Despite expectations for a strong 66%-67% adjusted gross margin, the company faces deeply negative profitability and ongoing cash burn, with technical analysis showing a sharp, high-volume breakdown.
Myriad Genetics (MYGN) Stock Sinks As Revenue Reset Deepens Loss Fears
Myriad Genetics (MYGN) stock sharply declined by nearly 47% after reporting a Q2 revenue reset and cutting full-year sales guidance, deepening fears of prolonged losses. Despite some clinical advancements in its oncology portfolio, the company experienced weakened average revenue per test and reduced gross margin guidance, indicating unresolved pricing and reimbursement challenges. Bears view this as confirmation of concerns regarding payer pushback and competitive pressure, while the company explicitly assumes no improvement in average revenue per test for the remainder of 2026.
Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness
Myriad Genetics (MYGN) saw its stock drop 49.0% after cutting its full-year 2026 revenue guidance to US$770 million–US$790 million, primarily due to weaker prenatal health test volumes. This downward revision challenges the company's investment narrative, which relies on its pivot to oncology and advanced genetic testing offsetting pressures in legacy and prenatal lines. Despite the prenatal test weakness, Myriad's partnership with Burning Rock Biotech for global HRD technology in oncology advanced, reinforcing the importance of its cancer testing segment for future growth.
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.75, Implies 7% Upside
Myriad Genetics, Inc.'s average 12-month price target has been lowered to $5.75 from $6.14 by 8 analysts, suggesting a potential 7% upside from its July 30 closing price. The target range for the stock is between $4 and $10 per share. Despite the cut, the consensus rating from 9 analysts remains "Hold," with 2 Buys, 5 Holds, and 2 Sells.
MYGN Stock Slides As Myriad Genetics Slashes 2026 Outlook
Myriad Genetics Inc. (MYGN) stock is down significantly after the company cut its 2026 revenue guidance, citing setbacks in its diagnostic pipeline and weaker market demand. Analysts have lowered price targets, and the stock is experiencing heavy selling pressure. The company faces challenges with profitability despite solid gross margins, and its financial overview highlights ongoing execution risk.
Myriad Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MYGN) 2026-08-01
Myriad Genetics, Inc. (MYGN) released its Q2 2026 earnings call presentation, detailing financial results. The company reported an EPS of -$0.25, missing estimates by $0.19, and revenue of $190.70M, which was down 10.51% year-over-year and missed estimates by $15.33M. This article provides access to the slide deck published in conjunction with the earnings call.
Myriad Genetics Is Maintained at Hold by TD Cowen
TD Cowen has reiterated its "Hold" rating for Myriad Genetics. The investment bank has also maintained its price target for the company.
Q2 2026 Myriad Genetics Inc Earnings Call Transcript
Myriad Genetics Inc (MYGN) reported mixed results for Q2 2026, with strong test volume growth in cancer care and mental health but an 11% year-over-year decline in total revenue. The company launched new products and made progress on pipeline milestones, yet faced significant challenges from elevated payer friction and declining average revenue per test. Consequently, MYGN lowered its full-year 2026 revenue guidance and suspended adjusted EBITDA guidance, reflecting a conservative outlook for the near future.
[10-Q] MYRIAD GENETICS INC Quarterly Earnings Report
Myriad Genetics Inc. (MYGN) has filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The company reported a net loss of $43.2 million for Q2 2026 and $77.3 million for the six months ended June 30, 2026. Revenue experienced a decrease compared to the prior year, attributed to lower reimbursement and changes in cash collection estimates, despite growth in Cancer Care Continuum and Mental Health testing volumes.
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.86, Implies 9% Upside
Myriad Genetics, Inc.'s average 12-month stock price target has been reduced from $6.14 to $5.86 by analysts, implying a 9% potential upside from its July 30 closing price. The consensus rating among 9 analysts remains "Hold," with a breakdown of 2 Buys, 5 Holds, and 2 Sells.
Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know
Myriad Genetics Inc. (NASDAQ: MYGN) shares dropped significantly by 37.80% in after-hours trading after the company reported disappointing second-quarter 2026 financial results, including lower revenue, an operating loss, and reduced full-year revenue guidance. The company also suspended its adjusted EBITDA outlook. Despite the overall weak performance, Myriad noted growth in its Cancer Care Continuum business and initiatives aimed at improving efficiency and profitability.
Myriad Genetics Lowers FY26 Rev Outlook
Myriad Genetics announced a reduction in its revenue outlook for fiscal year 2026. The company did not provide specific reasons for the revised forecast in the provided content.
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
Myriad Genetics announced its second quarter 2026 financial results, with revenue of $190.7 million, an 11% decrease year-over-year. The company is implementing new initiatives, including "Ascend," to improve efficiency, productivity, and scalability, and revised its full-year 2026 financial guidance. Despite challenges in Prenatal Health and payer friction, the Cancer Care Continuum business showed growth with new product launches and expanded offerings, and the company remains optimistic about its 2027 financial outlook.
Myriad Genetics Q2 Results: Revenue falls 11% YoY
Myriad Genetics Inc. experienced an 11% year-over-year revenue decline to $190.7 million in Q2 2026, leading to a significant 37.8% drop in stock price. The company reported a $38.9 million operating loss and suspended its full-year adjusted EBITDA guidance due to payer friction and lower average revenue per test. Consequently, Myriad Genetics also revised its full-year 2026 revenue guidance downward to $770-$790 million, reflecting ongoing challenges in reimbursement rates across its key segments despite some volume increases in cancer care and mental health.
Myriad Genetics (NASDAQ: MYGN) posts Q2 loss, lowers 2026 revenue view
Myriad Genetics (NASDAQ: MYGN) reported a Q2 2026 net loss of $43.2 million on revenues of $190.7 million, marking an 11% year-over-year decline. The company also lowered its full-year 2026 revenue guidance to $770–$790 million and suspended its Adjusted EBITDA outlook, citing challenges in Prenatal Health volumes and increased payer friction. Despite the losses, Myriad highlighted growth in its Cancer Care Continuum business, including new product launches and expansions, while also initiating a strategic review and efficiency program called Ascend to improve profitability and scalability.
Earnings call transcript: Myriad Genetics sinks after Q2 2026 revenue miss
Myriad Genetics reported Q2 2026 revenue of $190.7 million, missing Wall Street forecasts, and posted an adjusted loss of $0.25 per share, wider than expected. Shares fell sharply by over 31% in after-hours trading. The company cut its full-year revenue guidance and suspended adjusted EBITDA guidance, citing reimbursement challenges and collections issues, particularly affecting its hereditary cancer testing.
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
Myriad Genetics announced its second-quarter 2026 financial results, with revenue decreasing 11% year-over-year to $190.7 million. The company is implementing new initiatives, including "Ascend," to improve efficiency, productivity, and scalability, and has revised its full-year 2026 financial guidance. Despite challenges in Prenatal Health and payer friction, Myriad Genetics continues to advance its Cancer Care Continuum business with new product launches and expansions.
Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%
Myriad Genetics (NASDAQ:MYGN) reported Q2 CY2026 sales of $190.7 million, falling short of analyst estimates, and a non-GAAP loss of $0.25 per share, significantly below consensus. The company also lowered its full-year revenue guidance to $780 million at the midpoint from an earlier $870 million, leading to a 28.6% stock drop. Despite the poor quarterly performance and continued negative operating margins, analysts expect a rebound in revenue growth and a shift to positive EPS in the next 12 months.
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Myriad Genetics (MYGN) is set to report Q2 earnings this Thursday, with analysts expecting a 2.5% year-on-year revenue decline. The company missed revenue expectations last quarter, and its stock is down 9.5% over the last month, contrasting with a 4.4% average rise in the biotechnology segment. Investors are looking to see if Myriad Genetics can address past revenue misses and improve performance.
Myriad Genetics Inc (MYGN) Financial Health: Profitability & Balance Sheet Analysis
Myriad Genetics Inc (MYGN) has a stable financial status and high operating efficiency, ranking 93rd out of 199 companies in the Healthcare Equipment & Supplies industry with a score of 7.30. The company reported a Q4 revenue of $200.40 million, marking a 2.30% year-over-year increase, and a significant net profit increase of 34000.00% year-over-year. However, specific data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company.
